Logo image of SNOA

SONOMA PHARMACEUTICALS INC (SNOA) Stock Fundamental Analysis

NASDAQ:SNOA - Nasdaq - US83558L3033 - Common Stock - Currency: USD

2.97  +0.05 (+1.71%)

Fundamental Rating

2

Taking everything into account, SNOA scores 2 out of 10 in our fundamental rating. SNOA was compared to 195 industry peers in the Pharmaceuticals industry. SNOA scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. SNOA does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year SNOA has reported negative net income.
In the past year SNOA has reported a negative cash flow from operations.
SNOA had negative earnings in each of the past 5 years.
SNOA had a negative operating cash flow in each of the past 5 years.
SNOA Yearly Net Income VS EBIT VS OCF VS FCFSNOA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 5M -5M -10M

1.2 Ratios

Looking at the Return On Assets, with a value of -25.25%, SNOA is in line with its industry, outperforming 58.46% of the companies in the same industry.
The Return On Equity of SNOA (-78.37%) is comparable to the rest of the industry.
Industry RankSector Rank
ROA -25.25%
ROE -78.37%
ROIC N/A
ROA(3y)-29.93%
ROA(5y)-28.63%
ROE(3y)-73.9%
ROE(5y)-70.78%
ROIC(3y)N/A
ROIC(5y)N/A
SNOA Yearly ROA, ROE, ROICSNOA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -50 -100

1.3 Margins

The Gross Margin of SNOA (38.25%) is comparable to the rest of the industry.
In the last couple of years the Gross Margin of SNOA has declined.
The Profit Margin and Operating Margin are not available for SNOA so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 38.25%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y4.69%
GM growth 5Y-3.32%
SNOA Yearly Profit, Operating, Gross MarginsSNOA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50 -50 -100 -150

More info and screens

4

2. Health

2.1 Basic Checks

SNOA does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, SNOA has more shares outstanding
SNOA has less shares outstanding than it did 5 years ago.
The debt/assets ratio for SNOA has been reduced compared to a year ago.
SNOA Yearly Shares OutstandingSNOA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 1M 2M 3M 4M
SNOA Yearly Total Debt VS Total AssetsSNOA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5M 10M 15M 20M 25M

2.2 Solvency

Based on the Altman-Z score of -19.01, we must say that SNOA is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -19.01, SNOA is not doing good in the industry: 81.03% of the companies in the same industry are doing better.
A Debt/Equity ratio of 0.05 indicates that SNOA is not too dependend on debt financing.
SNOA has a Debt to Equity ratio (0.05) which is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0.05
Debt/FCF N/A
Altman-Z -19.01
ROIC/WACCN/A
WACC9.68%
SNOA Yearly LT Debt VS Equity VS FCFSNOA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 10M -10M 20M

2.3 Liquidity

A Current Ratio of 3.09 indicates that SNOA has no problem at all paying its short term obligations.
The Current ratio of SNOA (3.09) is comparable to the rest of the industry.
A Quick Ratio of 2.38 indicates that SNOA has no problem at all paying its short term obligations.
With a Quick ratio value of 2.38, SNOA perfoms like the industry average, outperforming 49.23% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 3.09
Quick Ratio 2.38
SNOA Yearly Current Assets VS Current LiabilitesSNOA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5M 10M 15M 20M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an nice 14.40% over the past year.
Looking at the last year, SNOA shows a quite strong growth in Revenue. The Revenue has grown by 12.18% in the last year.
The Revenue has been decreasing by -4.44% on average over the past years.
EPS 1Y (TTM)14.4%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%65.45%
Revenue 1Y (TTM)12.18%
Revenue growth 3Y4.2%
Revenue growth 5Y-4.44%
Sales Q2Q%9.16%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-166.72%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year25.45%
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
SNOA Yearly Revenue VS EstimatesSNOA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 10M 20M 30M
SNOA Yearly EPS VS EstimatesSNOA Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2017 2018 2019 2021 2024 2025 2026 0 -500 -1K

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

SNOA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for SNOA. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SNOA Price Earnings VS Forward Price EarningsSNOA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 5 10 15 20 25

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SNOA Per share dataSNOA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 6 8

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

SNOA does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

SONOMA PHARMACEUTICALS INC

NASDAQ:SNOA (7/3/2025, 8:09:55 PM)

2.97

+0.05 (+1.71%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)06-17 2025-06-17/amc
Earnings (Next)08-06 2025-08-06/amc
Inst Owners2.46%
Inst Owner Change63.98%
Ins Owners1.31%
Ins Owner Change0%
Market Cap4.81M
Analysts85.71
Price Target17.34 (483.84%)
Short Float %1.82%
Short Ratio0.02
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-15.52%
Min Revenue beat(2)-17.11%
Max Revenue beat(2)-13.93%
Revenue beat(4)0
Avg Revenue beat(4)-14.63%
Min Revenue beat(4)-17.11%
Max Revenue beat(4)-11.85%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.34
P/FCF N/A
P/OCF N/A
P/B 1.09
P/tB 1.09
EV/EBITDA N/A
EPS(TTM)-3.05
EYN/A
EPS(NY)-1.82
Fwd EYN/A
FCF(TTM)-0.1
FCFYN/A
OCF(TTM)-0.05
OCFYN/A
SpS8.82
BVpS2.72
TBVpS2.72
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -25.25%
ROE -78.37%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 38.25%
FCFM N/A
ROA(3y)-29.93%
ROA(5y)-28.63%
ROE(3y)-73.9%
ROE(5y)-70.78%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y4.69%
GM growth 5Y-3.32%
F-Score4
Asset Turnover1.04
Health
Industry RankSector Rank
Debt/Equity 0.05
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 57.97%
Cap/Sales 0.56%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.09
Quick Ratio 2.38
Altman-Z -19.01
F-Score4
WACC9.68%
ROIC/WACCN/A
Cap/Depr(3y)91.77%
Cap/Depr(5y)85.45%
Cap/Sales(3y)0.91%
Cap/Sales(5y)0.96%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)14.4%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%65.45%
EPS Next Y-166.72%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)12.18%
Revenue growth 3Y4.2%
Revenue growth 5Y-4.44%
Sales Q2Q%9.16%
Revenue Next Year25.45%
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y15.89%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y93.04%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y96.33%
OCF growth 3YN/A
OCF growth 5YN/A